BNP Paribas Financial Markets
MLTX icon

BNP Paribas Financial Markets’s MoonLake Immunotherapeutics MLTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.65M Buy
341,537
+101,699
+42% +$1.84M ﹤0.01% 1901
2026
Q1 		$4.47M Buy
239,838
+228,528
+2,021% +$3.79M ﹤0.01% 2115
2025
Q4 		$149K Buy
11,310
+4,014
+55% +$47.4K ﹤0.01% 4190
2025
Q3 		$52.3K Buy
7,296
+1,158
+19% +$60.4K ﹤0.01% 4584
2025
Q2 		$290K Sell
6,138
-190
-3% -$7.74K ﹤0.01% 3622
2025
Q1 		$247K Sell
6,328
-1,305
-17% -$56.2K ﹤0.01% 3592
2024
Q4 		$413K Buy
+7,633
New +$390K ﹤0.01% 3411

Other funds holding MLTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

BNP Paribas Financial Markets's MLTX Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its MoonLake Immunotherapeutics (MLTX) stake by 42% in Q2 2026, buying an estimated $1.84M and bringing the position to 341,537 shares worth $6.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1901.

BNP Paribas Financial Markets first reported a position in MLTX in Q4 2024 and has held it in 7 quarters since. 159 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • BNP Paribas Financial Markets held 341,537 shares of MoonLake Immunotherapeutics worth $6.65M as of Q2 2026.
  • BNP Paribas Financial Markets bought 101,699 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.84M.
  • MoonLake Immunotherapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #1901 holding.
  • BNP Paribas Financial Markets first reported a position in MoonLake Immunotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • 159 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.